Medical Patent News

RSS

Myriad Genetics issued new patent under license

Myriad Genetics has announced the issuance of Patent No. 6,911,466 entitled, "AB42 Lowering Agents". Myriad holds exclusive rights to the patent under a licensing agreement with Mayo Clinic. The patent covers methods of using a broad class of compounds known as selective amyloid beta 42 lowering agents (SALAs) to lower levels of the toxic peptide.

29 Jun 2005

Cordis patents infringed by Boston Scientific Stents

Cordis Corporation today announced that a U.S. District Court jury in Wilmington, Delaware found that Boston Scientific's Taxus drug-eluting stent and its Liberte and Express bare metal stents infringe Cordis' pioneering Palmaz patent for balloon expandable stents

21 Jun 2005

Brazil patent seizure threatens global trade and public health

With a number of other non-profit groups, ITSSD is calling attention to Brazil's threat to break U.S. patents on American AIDS drugs used as part of Brazil's government-funded treatment program.

19 Jun 2005

Neurocrine Biosciences issued new U.S. patent

Neurocrine Biosciences announced today the issuance of U.S. Patent No. 6,903,106 covering a novel polymorphic form (different crystal structure) of its proprietary compound indiplon for the treatment of insomnia.

16 Jun 2005

Immunomedics awarded U.S. and Australian patents

Immunomedics announced that it has received notices that the U.S. and Australian patent offices have allowed claims in respective patent applications covering methods for treating a wide range of autoimmune diseases using monoclonal antibodies that bind to the CD22 antigen present on B-lymphocytes.

16 Jun 2005

GenoMed to be awarded new patent, for treating acute kidney failure without dialysis

GenoMed announced today that the US Patent Office has allowed claims and will be following up with an issued patent shortly on the Company's protocol to treat acute kidney failure with a drug rather than the dialysis machine.

14 Jun 2005

CalbaTech subsidiary files patent for stem cell delivery device

CalbaTech announced today that its wholly owned subsidiary, LifeStem has filed a U.S. Patent Application for its Stem Cell Delivery Device. The patent is for the Device and Methods for Treatment of Necrotic Tissue using Stem Cells.

14 Jun 2005

Chemokine Therapeutics granted new U.S patent

Chemokine Therapeutics has announced that it has been granted U.S. Patent No. 6,875,738 relating to the use of its anti-cancer compound, CTCE-9908, in the treatment of cancer and inhibition of angiogenesis. CTCE-9908 is designed to block CXCR4, a receptor found on the surface of cancer cells.

14 Jun 2005

Lorus Therapeutics receives patent allowance to protect novel anticancer drug

Lorus Therapeutics today announced that its wholly owned subsidiary, GeneSense Technologies Inc. (GeneSense), has received notice from the European Patent Office of its intention to grant GeneSense's application for a patent of its novel antisense drug, GTI-2501.

9 Jun 2005

Arena Pharmaceuticals issued new patent

Arena Pharmaceuticals has announced that it was issued U.S. patent number 6,902,902, entitled "Human G Protein-Coupled Receptors and Modulators Thereof for the Treatment of Metabolic-Related Disorders," by the U.S. Patent Office.

8 Jun 2005

Vapotherm announces three pending U.S. patent applications

Vapotherm has announced the recent publication of three pending U.S. patent applications. Each of these applications represents significant milestones for the Company's intellectual property footprint.

8 Jun 2005

Bone Care International issued new patent

Bone Care International has announced that the U.S. Patent and Trademark Office has issued to it U.S. Patent Number 6,903,083 entitled "Stabilized hydroxyvitamin D."

8 Jun 2005

Biota makes major antiviral discovery

Biota Holdings Limited announced today that it has discovered a new class of orally-effective, potent antivirals against RSV (respiratory syncytial virus) infection.

7 Jun 2005

Biophan issued new patent for solution to enhance image quality of magnetic resonance imaging

Biophan Technologies has announced that the U.S. Patent No. 6,902,290 has been granted to the Company. The patent teaches the placement of an electronic sensor within medical devices that can offset the image artifacts that interfere with the quality of MRI imaging.

6 Jun 2005

Introgen wins European patent decision on p53 gene therapeutic

Introgen Therapeutics has announced that it was successful in winning the decision regarding its opposition of European Patent 0 390 323 before the European Patent Office (EPO) in which all claims directed to therapeutic applications of the p53 gene, the active component of Introgen's Advexin molecular therapy, were finally revoked by the EPO's Technical Board of Appeals.

3 Jun 2005

Nastech Pharmaceutical awarded new breast cancer patent

Nastech Pharmaceutical Company today announced that it has been awarded U.S. patent No. 6,894,026, entitled, "Long-acting Oxytocin Analogues for the Treatment and Prevention of Breast Cancer and Psychiatric Disorders."

31 May 2005

Targepeutics issued new U.S patent

Targepeutics has announced the issuance of U.S. Patent No. 6,884,603 for its genetically modified, mutated Interleukin 13 (IL-13) technology platform for the treatment of malignant glioma, a brain tumor (17,500 people annually; $200 million annual market).

31 May 2005

Targeted Genetics issued patent related to adeno-associated virus (AAV) technology platform

Targeted Genetics Corporation has announced the issuance of another patent related to the Company's leading adeno-associated virus (AAV) technology platform. U.S. patent #6,897,045, titled "Adeno-Associated Virus Vectors," was issued to the University of Iowa Research Foundation and is exclusively licensed to Targeted Genetics.

30 May 2005

Bioniche Life Sciences granted European patent

Bioniche Life Sciences has announced that it has had another patent granted on its core technology: Mycobacterial Cell Wall-DNA Complex (MCC). The European Patent Organization (EPO) granted the patent: - "Composition and Method for Inducing Apoptosis in Prostate Cancer Cells" (EPO1165106)

30 May 2005

Bioniche granted additional patent for mycobacterial cell wall technology

Bioniche Life Sciences Inc., a research-based, technology-driven human and animal health biopharmaceutical company, today announced that it has had a new patent issued by the United States Patent and Trademark Office (USPTO) on its core mycobacterial cell wall technology.

18 May 2005